Overview

Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the recurrence rate following total clearance of external genital warts (EGWs) when clearance has been obtained by imiquimod (3 applications per week for 4 weeks) followed by ablative therapy (laser or electrocautery therapy) with that from just ablative therapy treatment alone.
Phase:
Phase 4
Details
Lead Sponsor:
MEDA Pharma GmbH & Co. KG
Treatments:
Imiquimod